Page **1** of **5** >

ADVANCINGACCESS®

for **YEZTUGO**[®] (lenacapavir) injection 463.5 mg/1.5 mL

Policyholder Relationship to Patient:

Policyholder Relationship to Patient:

Secondary Insurance:

Subscriber Name:

Policyholder Name:

Plan Name:



PATIENT ENROLLMENT FORM

PHONE: **1-800-226-2056** | FAX: **1-800-915-3003** (Monday through Friday, 9 AM—8 PM EST)

PATIENT CONFIDENTIALITY: Patient confidentiality is of primary importance to us. All patient information will remain confidential. Information may be provided to clinicians, social workers, or family members when required to complete the enrollment process and coordinate medication assistance, and to credit bureaus to determine program eligibility with your consent within this Enrollment Form.

After submitting this form, a dedicated Acout to you to walk you through the next st					CLEAR FORM	
1. REQUESTED PATIENT SUPPORT REQUIR	RED				CHECK ALL BOXES THAT APPLY 🗸	
Benefits Investigation Co-pay Savings Pro		Authorization and eals Information			dication Assistance Program (MAP) gibility Screening	
2. GILEAD MEDICATION PRESCRIBED REC	UIRED				CHECK ONE OPTION ONLY 🗸	
Product Name: YEZTUGO (lenacapavir) Initiatio	on Dose (tablets/injections)	Maintenance	e Dose (inj	ections)	Oral Bridge (tablets)	
HEALTHCARE PROVIDER WILL ACQUIRE THE INJEC	TION THROUGH CHO	OOSE ONE OPTION	ONLY			
Specialty Pharmacy — If checked, enter Name: Would you like us to triage this enrollment form, which In-house Pharmacy — If checked, enter Name: Healthcare provider (HCP) will buy-and-bill				Yes □ No	, NPI #:	
3. PATIENT INFORMATION REQUIRED						
First Name:	Last Name:			MI:	Preferred Name:	
Address:	,	Apt/Unit #:		City:		
State:	ZIP Code:	Phone #: () -		_	Preferred Language:	
Email:		Date of Birth: / /			SSN (Last 4 digits):	
Alternate Contact Name:			e#:() –		Relationship:	
CONTACT AUTHORIZATION			1			
I authorize Advancing Access to provide me with information on my benefits and other communications that contain reference to the Advancing Access program or the ARx Patient Solutions Pharmacy through the following (select all that apply): Email						
4. INSURANCE INFORMATION REQUIRED	PLE	EASE INCLUDE A	COPY OF		NT AND BACK OF INSURANCE CARD(S), CLUDING MEDICAL AND PRESCRIPTION.	
Patient is uninsured (ie, no health insurance through any	public or private payer)—S	EE OPTIONAL "PAT	TIENT FINA	NCIAL INF	ORMATION" SECTION 5	
PRIMARY INSURANCE						
Primary Insurance: Is this a Medicare Part D plan			art D plan?	Yes	☐ No	
Plan Name: Insurance Phone #: (_		
Subscriber Name:	,					
Policyholder Name:	Policy #:			Group #:		

Rx Bin #:

Policy #:

Rx Bin #:

Is this a Medicare Part D plan?

Insurance Phone #: (

SECONDARY INSURANCE (Check this box if patient has secondary insurance coverage and include a copy [front and back] of insurance cards, if available)

Rx PCN #:

Group #:

Rx PCN #:

Yes No

THIS PAGE TO BE COMPLETED BY **PATIENT** OR **PATIENT'S REPRESENTATIVE** Page 2 of 5

ADVANCING ACCESS® YEZTUGO® (lenacapavir) MEDICATION ASSISTANCE PROGRAM (MAP) ENROLLMENT FORM PHONE: **1-800-226-2056** FAX: **1-800-915-3003**

PATIENT NAME DATE OF BIRTH

5. PATIENT FINANCIAL INFORMATION REQUIRED ONLY IF APPLYING FOR THE MEDICATION ASSISTANCE PROGRAM (MAP)						
Current annual household income: \$ (Documenta	tion for all sources of income may I	be required)				
Number of people in household supported by current annual income: 1 2 3 4 5 Other:						
ADDITIONAL INSURANCE INFORMATION						
Has the patient applied for the pre-exposure prophylaxis (PrEP) Drug Assistance Program (DAP)?						
What is the PrEP DAP status of the patient? Not applied Pending Wait-listed Denied (include denial letter) Not eligible, reason:						
Is the patient eligible for Medicaid? If No, state reason (if denied, include a copy of the denial letter):	☐ Yes ☐ No	If Yes, has the patient applied for Medicaid? If Yes, date of application://	Yes No			
Is the patient eligible for Medicare? If No, state reason (if denied, include a copy of the denial letter):	☐ Yes ☐ No	If Yes, has the patient applied for Medicare? If Yes, date of application://	Yes No			
Is the patient eligible for VA benefits?	☐ Yes ☐ No	If Yes, has the patient tried to obtain the medication through the VA?	Yes No			
Is the patient eligible for an insurance plan offered through a state in marketplace (also known as an exchange)? If No, state reason:	nsurance Yes No	If Yes, has the patient applied for an insurance plan offered through a state insurance marketplace (also known as an exchange)?	ce Yes No			
,,,,,,		If Yes, date of application:/				
PATIENT CONSENT/APPLICANT CONSENT AND	DECLARATIONS REQUIR	RED				
BY CHECKING THIS BOX , I understand that my prescription prescriber listed on this form, as my agent, to receive my prescrip medication.	otion on my behalf. My prescriber,	as my agent, will receive and then provide m				
BY SIGNING BELOW, I certify that all of the information provided in I understand that my prescription will be shipped directly to the pre agent, to receive my prescription on my behalf. My prescriber, as my will be shipped directly to the HCP.	scriber's office address listed on thi	s form (Section 7). I authorize the prescriber lis				
I understand that program assistance will terminate if Advancing Adforme. I understand that I may only use the free product received to will not offer the product for sale, resale, barter, or trade.	-					
I understand that completing this application does not ensure that I reimbursement or credit for this medication from any insurer, healt medication, or any cost for items associated with it, counted as par the application form, modify or discontinue this program, or terminal	h plan, or government program. If I t of my out-of-pocket cost for presc	am a member of a Medicare Part D plan, I wi ription drugs. I understand that the MAP reser	Il not seek to have this			
I authorize the MAP and its administrator to forward my prescription to a dispensing pharmacy on my behalf. Advancing Access may require me to submit proof of identity and income documentation to verify my eligibility into the MAP (eg, identification card, tax return, W-2, last two pay stubs, etc). I authorize Gilead and its third-party administrator to use the information provided on this form to obtain a personal credit report about me to verify the information on this form and determine my eligibility for the MAP. I authorize Gilead and its third-party administrator to use the information provided on this form to obtain a personal credit report about me to verify the information on this form and determine my eligibility for the MAP and forward my prescription to my pharmacy on the physician's behalf.						
SIGNATURE OF PATIENT or PATIENT'S AUTHORIZED REPRESENTATIVE UNDER F	EDERAL OR STATE LAW (REQUIRED):	DATE:	/ /			
PATIENT REPRESENTATIVE'S NAME (IF SIGNING FOR THE PATIENT):	PATIENT REPRESENTATIVE'S RELATIONSHI	P TO PATIENT: PHONE #:) –			

THIS PAGE TO BE COMPLETED BY PATIENT OR PATIENT'S REPRESENTATIVE

Page 3 of 5

ADVANCING ACCESS® YEZTUGO® (lenacapavir) MEDICATION ASSISTANCE PROGRAM (MAP) ENROLLMENT FORM PHONE: 1-800-226-2056 FAX: 1-800-915-3003

PATIENT NAME

DATE OF BIRTH

6. PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION REQUIRED

I understand that Gilead Sciences, Inc., and its vendors, agents, contractors, and other partners, (collectively, "Gilead") will need to obtain, review, use, and disclose my personal and medical information before I can receive assistance through the Advancing Access program (the "Program") and the Medication Assistance Program ("MAP"). Additional information about how Gilead may use my information can be found at https://www.gilead.com/privacy-statements.

Information to Be Disclosed: My personal information related to my use or potential use of YEZTUGO and related support that may be available to me, including through enrollment or participation in the Program or the MAP. This may include personally identifiable information and Protected Health Information ("PHI") as defined under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") as amended by the Health Information Technology for Economic and Clinical Health ("HITECH") Act (collectively, "Personal Information" or "PI"), including, but not limited to:

- General information about me, including my name, birth date, and contact information
- Information about my past, current, or future medical conditions, including information about my HIV-related status or treatment with this prescription medication and related medical conditions
- Information about my health benefits or health insurance coverage
- Financial information (as necessary), such as my income
- All information provided on this enrollment form and otherwise provided by me to the Program or MAP

Persons Authorized to Disclose and Use My Information: I authorize the following parties to disclose my PI to Gilead:

- My healthcare providers, including any pharmacy that fills my prescription medication. I understand that my pharmacy providers may receive remuneration for disclosing my PI pursuant to this authorization and/or making the communications to me that are described in this authorization
- Any health plans, including my health insurance company, or programs that provide me with healthcare benefits

I also authorize Gilead to redisclose my PI to the following parties:

- My healthcare providers, including the pharmacy that fills my prescription medication
- My health plans, including my health insurance company
- My authorized representative under federal or state law (if applicable)

Purposes for Which My Information May Be Used and Disclosed: My PI may be used and disclosed for the following purposes:

- Completing the enrollment process and verifying the information provided on my enrollment form, including confirming my identity and my use or potential use of the medication prescribed by my healthcare provider
- Establishing my eligibility for benefits from my health plan or other programs
- Providing financial assistance and reimbursement support, if I am eligible, and providing other applicable support, including information on third-party resources that may be able to assist me
- Communicating with my healthcare providers and coordinating my prescription and medication through a pharmacy or healthcare provider's office
- Contacting me to evaluate the effectiveness of the Program and/or the MAP
- Contacting me to provide marketing and informational communications from Gilead related to my medical condition, treatment. and/or my prescription medication, including educational information and promotional information about offers and services that may be of interest to me

Please continue onto next page >>>

THIS PAGE TO BE COMPLETED BY **PATIENT** OR **PATIENT'S REPRESENTATIVE**

Page **4** of **5** < >

ADVANCING ACCESS® YEZTUGO® (lenacapavir)
MEDICATION ASSISTANCE PROGRAM (MAP) ENROLLMENT FORM

PHONE: **1-800-226-2056** FAX: **1-800-915-3003**

PATIENT NAME

DATE OF BIRTH

/

6. PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION (CONTINUED) REQUIRED

(cont'd) Purposes for Which My Information May Be Used and Disclosed:

- Conducting sales and marketing research and analytics
- Gilead's internal business purposes and audit and compliance purposes
- Confirming my receipt of the prescribed Gilead medication through the MAP based on my communication preferences above
- Deidentifying the information I provide, which means removing elements like my name and address so that I am no longer reasonably identifiable
- Data aggregation, which may involve combining information about me with other information obtained by Gilead or its partners
- Meeting Gilead's legal requirements

Other Important Points:

- I understand that I may choose not to sign this authorization. If I refuse, my eligibility for health plan benefits or ability to obtain treatment from my healthcare providers will not change, but I will not have access to the support offered by the Program and/or the MAP
- Once I sign this Patient Authorization and my PI is transmitted to Gilead and its partners, I understand that state and federal
 privacy laws may no longer protect or prohibit the redisclosure of the PI disclosed to Gilead and its partners by my healthcare
 provider or others
- I understand that I am entitled to a copy of this signed authorization and that the authorization expires on the earlier of two (2) years from the date it is signed by me or sooner if required under the laws of the state in which I live
- I understand that I may cancel this authorization at any time by notifying Gilead at 1-800-226-2056 or patientsupport@gilead.com. If I cancel, Gilead will stop using this authorization to obtain, use, or disclose my PI after the cancellation date, but the cancellation will not affect uses or disclosures of any PI that have already been made pursuant to this authorization before the cancellation date

SIGNATURE OF PATIENT or PATIENT'S AUTHORIZED REPRESENTATIVE UNDER FED.	DATE (REQUIRED): / /		
PATIENT REPRESENTATIVE'S NAME (IF SIGNING FOR THE PATIENT):	PATIENT REPRESENTATIVE'S RELATIONSHIP TO PATIENT:	PHONE #: () –	

PHONE: 1-800-226-2056 FAX: 1-800-915-3003

ADVANCING ACCESS® YETTIGO® (lenacapavir) MEDICATION ASSISTANCE PROGRAM (MAP) ENROLI MENT FORM

ADTAITOITO ACCESS TEETCOS	(Terracapavii) IIII	11011 4001017	THOL I ROOM				
PATIENT NAME					DATE	OF BIRTH	/ /
7. PRESCRIBER INFORMATION	REQUIRED			1	MUST BE COM	MPLETED BY A HEAD	LTHCARE PROVIDER
Prescriber Name:			Facility Name	:			
Address:			City:			State:	ZIP Code:
Office Contact:			Phone #: ()	_	Fax #: ()	_
NPI #:	State License #:		PTAN #:			Tax ID #:	
8. MEDICAL INFORMATION/R	EASON FOR ENCO	UNTER F	EQUIRED	1	MUST BE COM	MPLETED BY A HEAD	LTHCARE PROVIDER
Reason for encounter (Please include ICI	o code[s]):						
9. PRESCRIPTION INFORMAT		MAP ONLY				TION FORM WHICH VI	
Patient First Name:		Last Name:				Date of Birth	n: / /
Is this the patient's first treatment of YEZT	UGO (lenacapavir)?	Yes No)	Known me	edication allerg	ies: (□None)	
,	FOR PATIE	NTS ON YEZTU	GO (CHOOSE C	ONE OPTION O	ONLY)	▼	
INITIATION (tablets/injections) YEZTUGO ORAL ONLY Oral 300 mg tablet QUANTITY: 4 R SIG: Take 2 tablets (600 mg) PO once of (600 mg) PO once on Day 2 YEZTUGO INJECTION ONLY Injection 927 mg SubQ QUANTITY: 2 SIG: Inject 2 x 1.5 mL subcutaneously of 6 months (26 weeks)	PEFILLS: 0 on Day 1, then 2 tablets $2 \times 1.5 \text{ mLs } \mid \text{ REFILLS: 1}$	YEZTU Injectic QUANT SIG: Inj every (MAINTENANC IGO INJECTIO on 927 mg Subic ITY: 2 x 1.5 mLs ect 2 x 1.5 mL st 6 months (26 we	N ONLY Q REFILLS: 1 ubcutaneously	y 5	ORAL BRID ORAL ONL OR	:: nce every to 6 months
REQUIRED Anticipated Start	Date: / /			•		oped directly to the preso	
10. PRESCRIBER CERTIFICATI	ON REQUIRED		,				
By signing this form, I certify that I am personally p and that it will be used as directed. I certify that I for the Medication Assistance Program ("MAP") is dispensed to the patient through the MAP from at 3 will be provided by me to such patient for his or any other person or patient. I will notify Gilead if to that patient, and I will ensure such medication is medication provided to me under the MAP. Health 1) the applicant identified in Section 3, including but confirming patient receipt of the prescribed Gilead in the appropriate written authorization from the patier requirements, in order to release the patient's person Advancing Access, conducting random audits to verify in Section 8. Gilead is authorized to contact me about by the patient, contact the patient directly to verify Ad enrollment form does not guarantee that assistance vat my office until it's provided to my patient, when ap to act on my behalf for the limited purposes of transm	orescribing or furnishing Gilead in will be supervising or coordination or coo	ing the patient's treate best of my know departy insurer. If apcertify that I will nor cation provided to rated representative of audits by Gilead a identity and verifying of any medications of any medication of a	atments, in accorda vledge. I certify the context of the context o	nce with law, an at I have not r nat medication processing such medication the patient ider (26-2056 within udit firm. I consolated by Act of 1996, all he purposes of a so outlined in the sensolated by a confirm the receive their Gilead r aws for authorize appropriate phartates, if not faxed	d verify that the in eceived and shall crovided to me by n or prescribe, pro tiffied in Section 3 and days. I certify the ent that Gilead mensing of medication a patient identified oplicable state heat ssessing the patier Patient Authorization participation in Advipt of Gilead medication on their deprescribers, whe macy designated but, prescription mus	oformation provided as part not seek reimbursement the MAP for the eligible pivide, furnish, or dispense as is not prescribed, provident I will not sell, resell, of ay perform random audits in provided to the prescriber in Section 3, if applicable. Ith information privacy law(tt's insurance coverage and on For Use and Disclosure of pancing Access. I understand ation through the MAP. I und behalf. I will receive and seen applicable. I authorize ARs y the patient utilizing their but will be the self.	of my patient's application for any Gilead medication patient identified in Section all or any portion thereof to ed, furnished, or dispensed fer for sale, trade, or barter and verification related to: through the MAP, including I certify that I have received (s), and any other applicable eligibility for participation in Fersonal Health Information that Gilead may, if authorized derstand that completing this cure my patient's medication in Patient Solutions Pharmacy benefit plan.
REQUIRED (sign one) NO STAMP ALLOWED PRESCRIBER	SIGNATURE (DISPENSE AS WRITT	EN): DATE	:: / /	PRESCR	IBER SIGNATURE (S	UBSTITUTIONS ALLOWED):	DATE: / /
11. HEALTHCARE PROVIDER C	ONSENT REQUIR	ED					
I understand that completing this enrollment form behalf. I will receive and secure my patient's medi							

PRESCRIBER SIGNATURE (REQUIRED): NO STAMP ALLOWED

facility may be subject to audits by Gilead and its third-party audit firm.

DATE:

prescribers, when applicable. Any medications supplied by Gilead as a result of this enrollment form are for the use of the patient named on this form only and shall not be sold, traded, bartered, transferred, returned for credit, or submitted to any third party (such as Medicare, Medicaid, or other benefit provider) for reimbursement. The medicine will be provided only to this eligible and enrolled patient at no charge of any kind. The information provided on this enrollment form is subject to random audits and verification. Gilead may change or cancel this program at any time; Gilead also reserves the right to terminate my patient's enrollment at any time. If medicine is not provided to my patient within 30 days of receipt, medicine must be returned to the ARX Patient Solutions Pharmacy. Healthcare

> **FAX COMPLETED FORM TO ADVANCING ACCESS AT** 1-800-915-3003